Logo image of INMD

INMODE LTD (INMD) Stock Fundamental Analysis

NASDAQ:INMD - IL0011595993 - Common Stock

15.02 USD
-0.05 (-0.33%)
Last: 9/10/2025, 8:00:02 PM
15.02 USD
0 (0%)
After Hours: 9/10/2025, 8:00:02 PM
Fundamental Rating

7

Overall INMD gets a fundamental rating of 7 out of 10. We evaluated INMD against 190 industry peers in the Health Care Equipment & Supplies industry. INMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. INMD may be a bit undervalued, certainly considering the very reasonable score on growth This makes INMD very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

INMD had positive earnings in the past year.
In the past year INMD had a positive cash flow from operations.
INMD had positive earnings in each of the past 5 years.
INMD had a positive operating cash flow in each of the past 5 years.
INMD Yearly Net Income VS EBIT VS OCF VS FCFINMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

The Return On Assets of INMD (25.23%) is better than 98.42% of its industry peers.
The Return On Equity of INMD (28.44%) is better than 97.89% of its industry peers.
The Return On Invested Capital of INMD (16.27%) is better than 96.32% of its industry peers.
The Average Return On Invested Capital over the past 3 years for INMD is significantly above the industry average of 8.46%.
The 3 year average ROIC (22.89%) for INMD is well above the current ROIC(16.27%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 25.23%
ROE 28.44%
ROIC 16.27%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
INMD Yearly ROA, ROE, ROICINMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

The Profit Margin of INMD (44.50%) is better than 97.89% of its industry peers.
In the last couple of years the Profit Margin of INMD has grown nicely.
INMD's Operating Margin of 28.54% is amongst the best of the industry. INMD outperforms 95.26% of its industry peers.
INMD's Operating Margin has declined in the last couple of years.
INMD has a Gross Margin of 79.98%. This is amongst the best in the industry. INMD outperforms 92.63% of its industry peers.
INMD's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 28.54%
PM (TTM) 44.5%
GM 79.98%
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
INMD Yearly Profit, Operating, Gross MarginsINMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INMD is creating value.
Compared to 1 year ago, INMD has less shares outstanding
INMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INMD Yearly Shares OutstandingINMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
INMD Yearly Total Debt VS Total AssetsINMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

INMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.84
WACC8.82%
INMD Yearly LT Debt VS Equity VS FCFINMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

A Current Ratio of 9.60 indicates that INMD has no problem at all paying its short term obligations.
INMD has a Current ratio of 9.60. This is amongst the best in the industry. INMD outperforms 91.58% of its industry peers.
INMD has a Quick Ratio of 8.58. This indicates that INMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.58, INMD belongs to the top of the industry, outperforming 91.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.6
Quick Ratio 8.58
INMD Yearly Current Assets VS Current LiabilitesINMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for INMD have decreased by -4.04% in the last year.
The Earnings Per Share has been growing by 22.97% on average over the past years. This is a very strong growth
Looking at the last year, INMD shows a decrease in Revenue. The Revenue has decreased by -3.61% in the last year.
Measured over the past years, INMD shows a very strong growth in Revenue. The Revenue has been growing by 20.35% on average per year.
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%

3.2 Future

Based on estimates for the next years, INMD will show a small growth in Earnings Per Share. The EPS will grow by 1.43% on average per year.
Based on estimates for the next years, INMD will show a small growth in Revenue. The Revenue will grow by 0.74% on average per year.
EPS Next Y-9.82%
EPS Next 2Y-1.69%
EPS Next 3Y1.43%
EPS Next 5YN/A
Revenue Next Year-8.24%
Revenue Next 2Y-1.7%
Revenue Next 3Y0.74%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INMD Yearly Revenue VS EstimatesINMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
INMD Yearly EPS VS EstimatesINMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 7.91, which indicates a rather cheap valuation of INMD.
95.79% of the companies in the same industry are more expensive than INMD, based on the Price/Earnings ratio.
INMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.03.
INMD is valuated reasonably with a Price/Forward Earnings ratio of 8.73.
Compared to the rest of the industry, the Price/Forward Earnings ratio of INMD indicates a rather cheap valuation: INMD is cheaper than 95.79% of the companies listed in the same industry.
INMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 7.91
Fwd PE 8.73
INMD Price Earnings VS Forward Price EarningsINMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, INMD is valued cheaply inside the industry as 99.47% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, INMD is valued cheaply inside the industry as 96.84% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.13
EV/EBITDA 2.24
INMD Per share dataINMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The excellent profitability rating of INMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.34
EPS Next 2Y-1.69%
EPS Next 3Y1.43%

More info and screens

0

5. Dividend

5.1 Amount

INMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMODE LTD

NASDAQ:INMD (9/10/2025, 8:00:02 PM)

After market: 15.02 0 (0%)

15.02

-0.05 (-0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)10-28 2025-10-28/bmo
Inst Owners70.51%
Inst Owner Change-14.05%
Ins Owners10.65%
Ins Owner ChangeN/A
Market Cap949.41M
Analysts72.31
Price Target16.58 (10.39%)
Short Float %5.78%
Short Ratio2.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.54%
Min EPS beat(2)-13.69%
Max EPS beat(2)10.61%
EPS beat(4)2
Avg EPS beat(4)-3.62%
Min EPS beat(4)-20.27%
Max EPS beat(4)10.61%
EPS beat(8)3
Avg EPS beat(8)-6.64%
EPS beat(12)7
Avg EPS beat(12)-0.75%
EPS beat(16)11
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-2.62%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-9.96%
Max Revenue beat(4)0.53%
Revenue beat(8)1
Avg Revenue beat(8)-7%
Revenue beat(12)5
Avg Revenue beat(12)-3.84%
Revenue beat(16)9
Avg Revenue beat(16)-1.49%
PT rev (1m)0%
PT rev (3m)-5.8%
EPS NQ rev (1m)8.96%
EPS NQ rev (3m)-29.56%
EPS NY rev (1m)-6.87%
EPS NY rev (3m)-6.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.09%
Revenue NY rev (1m)-3.24%
Revenue NY rev (3m)-4.41%
Valuation
Industry RankSector Rank
PE 7.91
Fwd PE 8.73
P/S 2.36
P/FCF 9.13
P/OCF 9.08
P/B 1.51
P/tB 1.51
EV/EBITDA 2.24
EPS(TTM)1.9
EY12.65%
EPS(NY)1.72
Fwd EY11.45%
FCF(TTM)1.65
FCFY10.95%
OCF(TTM)1.65
OCFY11.02%
SpS6.35
BVpS9.94
TBVpS9.94
PEG (NY)N/A
PEG (5Y)0.34
Profitability
Industry RankSector Rank
ROA 25.23%
ROE 28.44%
ROCE 17.86%
ROIC 16.27%
ROICexc 79.63%
ROICexgc 79.63%
OM 28.54%
PM (TTM) 44.5%
GM 79.98%
FCFM 25.9%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexcg growth 3Y-60.68%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score7
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 81.89%
Cap/Sales 0.15%
Interest Coverage 250
Cash Conversion 90.67%
Profit Quality 58.19%
Current Ratio 9.6
Quick Ratio 8.58
Altman-Z N/A
F-Score7
WACC8.82%
ROIC/WACC1.84
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-4.04%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%38.24%
EPS Next Y-9.82%
EPS Next 2Y-1.69%
EPS Next 3Y1.43%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.61%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%10.59%
Revenue Next Year-8.24%
Revenue Next 2Y-1.7%
Revenue Next 3Y0.74%
Revenue Next 5YN/A
EBIT growth 1Y-14.49%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-39.83%
EBIT Next 3Y-11.16%
EBIT Next 5YN/A
FCF growth 1Y-40.81%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-40.87%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%